EVENTS · NVO
PEERS
EARNINGS
Novo Nordisk A/S Sponsored ADR is a healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. The company’s current business is organized around diabetes and obesity care, where it offers treatments and related devices for chronic metabolic conditions, and rare disease, where it serves patients with specialized therapies for blood disorders and endocrine disorders. Novo Nordisk A/S Sponsored ADR works with patients, healthcare professionals, and care providers across global markets, supplying medicines used in long-term disease management. As a sponsored ADR, it gives investors a U.S.-traded representation of the company’s underlying shares while reflecting the performance of its international healthcare operations. The company is headquartered in Bagsværd, Denmark, and remains a major participant in the global pharmaceutical industry through its focus on chronic disease treatment and specialty care.
Novo Nordisk raised its full year forecast after strong Wegovy sales topped estimates, driving the stock higher
| Series | 1W | 1M |
|---|---|---|
| NVO | +10.1% | +12.4% |
| Peers | +6.7% | +14.0% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 82 | 65 |
| Series | 1W | 1M |
|---|---|---|
| NVO | +10.1% | +12.4% |
| Peers | +6.7% | +14.0% |
| Sector · Health Care | +5.6% | +13.5% |
| SPY | −0.7% | −1.6% |
| Percentile rank vs S&P 500 | 82 | 65 |
